These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 32469437)

  • 1. A Comprehensive Updated Review on SARS-CoV-2 and COVID-19.
    Ren YR; Golding A; Sorbello A; Ji P; Chen J; Saluja B; Witzmann K; Arya V; Reynolds KS; Choi SY; Nikolov NP; Sahajwalla C
    J Clin Pharmacol; 2020 Aug; 60(8):954-975. PubMed ID: 32469437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.
    Schijns V; Lavelle EC
    Eur J Immunol; 2020 Jul; 50(7):932-938. PubMed ID: 32438473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin therapy and SAR-COV-2: an available and potential therapy?
    Abdel-Latif RG; Mohammed S; Elgendy IY
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):333-334. PubMed ID: 32379307
    [No Abstract]   [Full Text] [Related]  

  • 4. COVID-19: Small-Molecule Clinical Trials Landscape.
    Ferreira LLG; Andricopulo AD
    Curr Top Med Chem; 2020; 20(18):1577-1580. PubMed ID: 32862824
    [No Abstract]   [Full Text] [Related]  

  • 5. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.
    Zhao M
    Int J Antimicrob Agents; 2020 Jun; 55(6):105982. PubMed ID: 32305588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of novel coronavirus and progress toward treatment and vaccine.
    Khan MM; Noor A; Madni A; Shafiq M
    Rev Med Virol; 2020 Jul; 30(4):e2116. PubMed ID: 32495979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
    Nisole S; Saulnier A; Gatignol A
    Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
    [No Abstract]   [Full Text] [Related]  

  • 8. COVID-19: The Need for Immunoprevention at Industrial Scale.
    Halstead SB
    Am J Trop Med Hyg; 2020 Jun; 102(6):1151. PubMed ID: 32274985
    [No Abstract]   [Full Text] [Related]  

  • 9. Audio Interview: Approaches to Covid-19 Vaccines and Antivirals.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 Apr; 382(16):e58. PubMed ID: 32320592
    [No Abstract]   [Full Text] [Related]  

  • 10. Activation of TLR7 and Innate Immunity as an Efficient Method Against COVID-19 Pandemic: Imiquimod as a Potential Therapy.
    Poulas K; Farsalinos K; Zanidis C
    Front Immunol; 2020; 11():1373. PubMed ID: 32612613
    [No Abstract]   [Full Text] [Related]  

  • 11. Microbicidal actives with virucidal efficacy against SARS-CoV-2.
    Ijaz MK; Whitehead K; Srinivasan V; McKinney J; Rubino JR; Ripley M; Jones C; Nims RW; Charlesworth B
    Am J Infect Control; 2020 Aug; 48(8):972-973. PubMed ID: 32461067
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination prevention for COVID-19.
    Cohen MS; Corey L
    Science; 2020 May; 368(6491):551. PubMed ID: 32381692
    [No Abstract]   [Full Text] [Related]  

  • 13. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
    Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
    Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chloroquine as a prophylactic agent against COVID-19?
    Gendrot M; Javelle E; Clerc A; Savini H; Pradines B
    Int J Antimicrob Agents; 2020 Jun; 55(6):105980. PubMed ID: 32294495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19: Some clinical questions after the first 4 months.
    Bassetti M; Ansaldi F; Icardi G; Pelosi P; Robba C; Taramasso L; Trucchi C; Vena A; Giacobbe DR
    Eur J Clin Invest; 2020 Jul; 50(7):e13326. PubMed ID: 32562550
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimizing COVID-19 Candidate Therapeutics: Thinking Without Borders.
    Rayner CR; Smith PF; Hershberger K; Wesche D
    Clin Transl Sci; 2020 Sep; 13(5):830-834. PubMed ID: 32212378
    [No Abstract]   [Full Text] [Related]  

  • 17. John-Arne Røttingen.
    Mullard A
    Nat Rev Drug Discov; 2020 May; 19(5):302-303. PubMed ID: 32286497
    [No Abstract]   [Full Text] [Related]  

  • 18.
    Siddiqui R; Khan NA
    ACS Chem Neurosci; 2020 Aug; 11(16):2391-2392. PubMed ID: 32786329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2: a time for clear and immediate action.
    Poland GA
    Lancet Infect Dis; 2020 May; 20(5):531-532. PubMed ID: 32243818
    [No Abstract]   [Full Text] [Related]  

  • 20. An Urgent Need for "Common Cold Units" to Study COVID-19.
    Halstead SB
    Am J Trop Med Hyg; 2020 Jun; 102(6):1152-1153. PubMed ID: 32274988
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 25.